Helen Tayton-Martin
2019
In 2019, Helen Tayton-Martin earned a total compensation of $1.4M as Chief Business Officer at Adaptimmune Therapeutics, a 6% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $133,782 |
|---|---|
| Option Awards | $766,900 |
| Salary | $424,703 |
| Other | $29,705 |
| Total | $1,355,090 |
Tayton-Martin received $766.9K in option awards, accounting for 57% of the total pay in 2019.
Tayton-Martin also received $133.8K in non-equity incentive plan, $424.7K in salary and $29.7K in other compensation.
Rankings
In 2019, Helen Tayton-Martin's compensation ranked 7,834th out of 13,971 executives tracked by ExecPay. In other words, Tayton-Martin earned more than 43.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,834 out of 13,971 | 44th |
Division Manufacturing | 3,083 out of 5,701 | 46th |
Major group Chemicals And Allied Products | 1,162 out of 2,200 | 47th |
Industry group Drugs | 992 out of 1,886 | 47th |
Industry Biological Products, Except Diagnostic Substances | 225 out of 389 | 42nd |
Source: SEC filing on April 20, 2020.
Tayton-Martin's colleagues
We found four more compensation records of executives who worked with Helen Tayton-Martin at Adaptimmune Therapeutics in 2019.